Definium Therapeutics price target raised to $36 from $20 at RBC Capital

RBC Capital raised the firm’s price target on Definium Therapeutics (DFTX) to $36 from $20 and keeps an Outperform rating on the shares. Following the firm’s Psychedelics Symposium and discussions with the management, the firm has increased expectations for lead drug DT120’s long-term sales opportunity, the analyst tells investors in a research note.